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Purpose: To establish the incidence of Stargardt disease (STGD) in the United Kingdom and deﬁne baseline
characteristics of newly diagnosed patients.
Design: Prospective epidemiologic study undertaken under the auspices of the British Ophthalmological
Surveillance Unit (BOSU).
Participants: New incident cases of STGD in the United Kingdom reported by ophthalmologists to BOSU
during a 12-month period, from June 1, 2012, to June 1, 2013.
Methods: Once a new case of STGD was reported, an incident questionnaire was sent to the reporting
ophthalmologist, followed by a follow-up questionnaire (when required) 6 months later.
Main Outcome Measures: Patient demographics, baseline characteristics including visual acuity, and
ﬁndings on slit-lamp biomicroscopy, as well as diagnostic technologies undertaken at baseline and their ﬁndings,
including electrophysiology, fundus autoﬂuorescence, ﬂuorescein angiography, and genetic testing.
Results: A total of 81 new cases of STGD were reported during the 12-month period of the study; baseline
data were obtained on 70 (86%) of these. These results suggest an annual incidence in the United Kingdom of
between 0.110 and 0.128 per 100 000 individuals. The median age of patients at presentation was 27 years, the
majority were British (77%), and most (90%) were symptomatic, with a median visual acuity of 0.52 logMAR
(Snellen equivalent 20/66).
Conclusions: Even considering possible limitations related to incomplete ascertainment, this is the ﬁrst
prospective epidemiology study that provides indication of the incidence of STGD in the United Kingdom. The
incidence of STGD estimated herein appears to be lower than that repeatedly quoted in the literature. Fundus
autoﬂuoresence and electrophysiology testing are most commonly used for the evaluation of patients with
STGD. Ophthalmology Retina 2017;1:508-513 ª 2017 by the American Academy of Ophthalmology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Stargardt disease (STGD) and fundus ﬂavimaculatus (FFM)
are synonymous terms used to refer to the same recessively
inherited macular dystrophy that affects photoreceptor (PR)
and retinal pigment epithelium (RPE).1,2 The condition was
ﬁrst recognized in 1909 by Stargardt, who described 7
patients with a recessively inherited macular dystrophy
characterized by macular atrophy surrounded by deep
yellow-white retinal lesions.1 Other features of the disease
include initial loss of vision without clinical signs on
funduscopy.1 The term FFM was later coined by
Franceschetti, who described a disease characterized by
the presence of “ﬁshlike” (pisciform) deep yellow-white
retinal lesions, now referred to as “ﬂecks.”2 Since the
original description, there have been numerous studies
evaluating different aspects of this inherited retinal disorder.
The incidence of STGD was estimated to be between 1 in
8000 and 1 in 10 000 in the United States.3 The 1 in 10 000
incidence has been repeatedly quoted in the literature.3e5
This estimate, however, does not derive from an epidemi-
ology study but rather from Blacharski’s observation that
STGD is more common than retinoblastoma (the incidence
of which Blacharski estimated to be 1 in 15 000) but
less common than retinitis pigmentosa (which Blacharski508  2017 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Incestimated to occur in 1 in 5000 individuals). As new ther-
apies for STGD are currently being investigated, including
embryonic stem cellederived retinal pigment epithelial cell
transplantation6 and ABCA4 gene replacement therapy using
the StarGen,7 elucidating the incidence and baseline
characteristics of patients presenting with this macular
dystrophy would be invaluable to plan future therapeutic
strategies. This was thus the purpose of the study
presented herein. In order to accomplish this purpose, we
undertook a prospective population-based epidemiologic
study to determine the incidence of STGD in the United
Kingdom and gain knowledge on the baseline characteristics
of patients presenting with this retinal disorder.Methods
The study was conducted in according with the tenets of the
Declaration of Helsinki. Ethical approval was sought and obtained
from the North of Scotland National Research Ethics Service and
the NHS Grampian Research and Development Committees before
the initiation of the study.
Patients with newly diagnosed STGD (new incident cases) were
identiﬁed prospectively through active surveillance by the British.
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period from July 2012 to June 2013, both inclusive. This surveil-
lance scheme involves all ophthalmologists in the United Kingdom
(consultants and associate specialists). Before the study was initi-
ated, the BOSU informed ophthalmologists about the new ocular
conditions under investigation (STGD), including the case deﬁni-
tion. For the purpose of the study, STGD was deﬁned as a reces-
sively inherited retinal dystrophy presenting at any age with a
number of characteristics, which include macular changes
(mottling, bull’s-eye appearance, and/or atrophy) and/or retinal
ﬂecks (active or resorbed) with relative peripapillary sparing. An
active ﬂeck is deﬁned as an accumulation of yellow material at the
level of the RPE, which appears as an area of hypoﬂuorescence on
fundus ﬂuorescein angiography (FFA) and as an area of increased
signal on autoﬂuorescence (AF) imaging. A resorbed ﬂeck is
deﬁned as a small focus of depigmentation or atrophy in the RPE,
appearing as an area of hyperﬂuorescence on FFA and reduced
AF signal.
Genetic conﬁrmation (i.e., presence of disease-causing varia-
tions in both alleles of the ABCA4) was not required for the
diagnosis of the cases reported. The diagnosis was made by ﬁnd-
ings on clinical examination (as per the above description) and
ancillary studies including pattern and full-ﬁeld electroretinog-
raphy (PERG and FFERG, respectively), ﬂuorescein angiography,
and fundus AF. A ﬂat or very reduced PERG (with our without
FFERG abnormalities), dark choroid on FFA, and multiple foci or
reduced or increased signal on fundus AF imaging with relative
peripapillary sparing would be suggestive of the diagnosis.
Consultation with national experts on inherited retinal diseases
took place before the initiation of the study to set the case deﬁnition
used.
At the end of each month, a report card was sent out by BOSU
to ophthalmologists in the United Kingdom (UK); ophthalmolo-
gists then returned the card to BOSU specifying whether a new
case had been seen during that month (or whether this had not been
the case). After case notiﬁcation, a study card with the case deﬁ-
nition and incident questionnaire was sent to the reporting
ophthalmologists by the research group. If the reporting ophthal-
mologist indicated that further investigations were planned for the
patient, a further follow-up questionnaire was sent 6 months after
receipt of the incident questionnaire. For this study, units that had
not reported cases but that were covering a population sufﬁciently
large to have been expected to have evaluated a case of STGD
were independently contacted to conﬁrm the absence of incident
STGD cases during the 12-month study period.
Before the initiation of the study, retinal specialists from all
over the UK, who were thought to form largely the group that
would be most likely reporting new incident cases, were
approached and informed about the upcoming study and asked to
provide feedback on the study card (case deﬁnition) and ques-
tionnaires developed for the study. Their input was incorporated in
the ﬁnal materials for the study.
The incident questionnaire collected data on age of onset,
gender, ethnicity, family history, and symptoms at presentation.
Baseline examination ﬁndings including best-corrected visual
acuity and fundus features and results of ancillary studies including
electrophysiology, AF, FFA, and genetic testing, if available, were
also sought. Ophthalmologists were speciﬁcally questioned in the
incident questionnaire as to whether further testing was planned in
the reported case and, if so, follow-up questionnaires were sent at 6
months to collect the results of these tests. To avoid possible
reporting duplications related to the fact that patients could be
diagnosed in one center and referred to a tertiary center specializing
in the diagnosis and evaluation of patients with inherited retinal
disorders, nonidentiﬁable details (date of birth and ﬁrst part ofpostcode) were collected from each patient in the incident ques-
tionnaire. In the event that a patient was referred to a different
hospital, the 2 separate questionnaires would have the same patient
details and would be counted as 1 single patient, if this was
conﬁrmed to be the case. Reporting ophthalmologists were
encouraged to contact KSC or NL in case of doubt about the
possible diagnosis of STGD; in some instances, anonymized im-
ages and other investigations were, thus, provided to and analyzed
by 2 of the authors (KSC and NL) to conﬁrm or exclude the
diagnosis of STGD.
Results
New Incident Cases Reported
From July 2012 to June 2013 (both months inclusive), a total of 86
cards were returned to BOSU reporting new incident cases. Of
these, 5 cases were excluded: 2 because although they were
initially thought to be STGD, they were later diagnosed as cone
dystrophy and pattern dystrophy by the reporting ophthalmologist;
and 3 because they had been diagnosed outside the speciﬁed study
period. Thus, there were 81 incident cases; baseline data were
obtained through the incident questionnaire in 70 of 81 new inci-
dent cases (86%), and follow-up data were obtained in 6 of 7
(85.7%) of the 6-month questionnaires sent. During the study
period, there were a total of 1251 reporting ophthalmologists for all
BOSU studies and the overall card return rate was 74.5%.
Incidence of Stargardt Disease in the United
Kingdom
In 2012, the UK Ofﬁce for National Statistics projected the pop-
ulation to be 63 700 000. Considering all 81 cases reported to
BOSU, the estimated incidence of STGD in the UK would be
0.127 per 100 000 per year (95% conﬁdence interval,
0.099e0.155). If only the 70 cases of STGD for which data were
available to the researchers (questionnaires returned) and the
diagnosis of STGD conﬁrmed were to be included, then the esti-
mated annual incidence of STGD in the UK would be 0.110 per
100 000 (95% conﬁdence interval, 0.084e0.136) of the general
population per year. Therefore these results would suggest an
annual incidence of STGD-FFM in the UK of between 0.110 and
0.127 per 100 000 individuals per year.
Patient Demographics
The majority of reported cases of STGD affected young adults,
with a median age of 27 years (mean 27.4 years; range 5e64
years). The majority were white British (77%), with a higher
proportion of female subjects affected (61.4%). A summary of
the baseline characteristics of incident cases is presented in
Tables 1 to 3.
Symptoms
The vast majority of cases were symptomatic (90.0%), with
reduced vision being the most common symptom (80.0%),
followed by nyctalopia (12.9%) and photophobia (11.4%).
Visual Acuity
Visual acuity at presentation was recorded in either Snellen or
logarithm of the minimum angle of resolution (logMAR). For the
purpose of this study, Snellen visual acuity values were converted
into logMAR acuities using standard conversion tables. Visual509
Table 3. Retinal Imaging Results
N (%)
Fundus autoﬂuorescence*
Macula
Normal 0 (0)
Reduced signal (atrophy) 17 (53.1)
Foci of increased signal 18 (56.3)
Foci of reduced signal 7 (21.9)
Midperipheral/peripheral retina
Normal 24 (75.0)
Reduced signal (atrophy) 3 (9.4)
Foci of increased signal 4 (12.5)
Foci of reduced signal 0 (0)
Fundus ﬂuorescein angiogramy
Normal 1 (7.1)
Dark choroid 12 (85.7)
Window defect (atrophy) 5 (35.7)
*Fundus autoﬂuorescence features were reported in 32 of 70 patients.
yFundus ﬂuorescein angiography features were reported in 14 of 70 patients.
Table 1. Clinical Characteristics of 70 Incident Cases of Stargardt
Disease at Presentation
Mean age (SD) 27.4 (17.3)
Female, n (%) 43 (61.4)
Ethnicity, n (%)
White 57 (81.4)
Black 3 (4.3)
Asian Indian 7 (10.0)
Asian 3 (4.3)
Symptoms, n (%)
Reduced visual acuity 56 (80.0)
Nyctalopia 9 (12.9)
Photophobia 8 (11.4)
Asymptomatic 7 (10.0)
Other 8 (11.4)
SD ¼ standard deviation.
Ophthalmology Retina Volume 1, Number 6, November/December 2017acuities at presentation varied between 0.08 and 2.0 (Snellen
equivalent of 20/16 and 20/2000, respectively) with a median
visual acuity of 0.52 (20/66). Twenty-one patients (30%) had a
visual acuity of 0.30 (20/40) or better in the best-seeing eye; 31
patients (44.3%) had a visual acuity of 0.80 (20/126) or worse.
Clinical Features on Slit-Lamp Biomicroscopy
The diagnosis of STGD was based on the speciﬁc case deﬁnition
that was published by BOSU for the duration of the study. One of
the key features of the disease was the presence of active or resorbed
ﬂecks. In our study, 50 patients (71%) had active retinal ﬂecks in the
macula and/or midperipheral retina of 1 or both eyes. In 7 of these
50 patients, ﬂecks were only detected on AF imaging; the rest were
evident on slit-lamp biomicroscopy. In the remaining 20 patients in
whom ﬂecks were not present, the diagnosis of STGD was sup-
ported by a family history of STGD (n ¼ 7) (details in Table 4),
conﬁrmed ABCA4 mutations on genetic analysis (n ¼ 3), or the
presence of a severely reduced (ﬂat) PERG (n ¼ 11).
In the majority of patients (n ¼ 38, 54.3%), active macular
ﬂecks were present, as identiﬁed clinically (n ¼ 36), on AFTable 2. Visual Acuity and Fundus Features* in 70 Incident Cases
of Stargardt Disease
Feature N (%)
Visual acuity, Snellen (logMAR)
6/12 (0.30) or better 41
6/18 (0.48) to 6/60 (1.0) 81
6/60 (1.0) or worse 16
Macular ﬁndings
None 3 (4.3)
Pigment mottling 20 (28.6)
Bull’s-eye appearance 17 (24.3)
Atrophy 26 (37.1)
Flecks 36 (51.4)
Midperipheral/peripheral retinal ﬁndings
None 52 (74.3)
Flecks 7 (10.0)
Atrophy 3 (4.3)
Other 3 (4.3)
logMAR ¼ logarithm of the minimum angle of resolution.
*Findings based on slit-lamp biomicroscopy alone.
510imaging (n ¼ 2), or both. The second most common clinical
ﬁnding at the macula was atrophy, which was detected in over one-
third (n ¼ 26, 37.1%) of patients. Macular pigment mottling and
bull’s-eye maculopathy were present in approximately one-quarter
of cases (28.6% and 24.3%, respectively). There were no fundus
abnormalities in the midperipheral and peripheral retina in 52 cases
(74.3%). The most common sign in the retinal midperiphery was
active ﬂecks, present in 12 (17.1%) patients.Findings on Fundus Autoﬂuorescence Imaging
AF was the imaging technology most frequently used to aid in
the diagnosis of STGD (Table 3). AF imaging was obtained in
32 patients (45.7%); an abnormal AF signal was found in all
cases. In the majority of patients (n ¼ 25, 78.2%), foci of
increased or reduced AF signal (representing active and
resolved ﬂecks, respectively) were detected on AF imaging. A
homogeneous background of fundus AF was observed in the
midperipheral retina in three-quarters of patients (n ¼ 24,
75.0%). Macular atrophy (central area of reduced AF signal) was
present in 17 (53.1%). In 7 of the 32 who underwent AF
(21.9%), ﬂecks not visible on clinical examination were identiﬁed
on AF; in 2 (6.2%), AF identiﬁed macular atrophy that was not
detected clinically.Table 4. Family History of Patients with No Retinal Flecks on
Examination and on Fundus Autoﬂuorescence Imaging
Patient Number Positive Family History of STGD
1 2 sisters
2 Father
3 Father
4 1 brother
5 1 sister, 1 maternal uncle
6 1 paternal grandmother
7 1 brother
STGD ¼ Stargardt disease.
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FFA was infrequently used in the evaluation of patients with
STGD (n ¼ 14, 20.0%) and revealed a dark choroid in most cases
(n ¼ 12, 85.7%).
Findings on Electrophysiology
Electrophysiology testing was undertaken in 50 patients (71.4%),
including FFERG and PERG. In 45 of these 50 patients (90%),
reduced macular function with normal FFERG (group 1 STGD)
was found in most cases (n ¼ 51, 73.3%),8 followed by reduced
macular and peripheral cone function (group 2, n ¼ 11, 15.6%)8
and reduced macular and peripheral rod and cone function
(group 3, n ¼ 8, 11.1%).8 In 5 patients (10%)
electrophysiology testing was reported to be within normal
limits. In these 5 patients, the diagnosis of STGD was based
on the presence of ﬂecks clinically (n ¼ 3), dark choroid on
FFA (n ¼ 2), and ABCA4 mutations (n ¼ 1, 2 disease-causing
alleles identiﬁed).
Genetic Testing
Ten patients underwent genetic testing; in 9, ABCA4 mutations
were identiﬁed in 1 (n ¼ 4) or 2 (n ¼ 5) alleles. Details of
the allelic mutations found were given in 5 patients; these
included c.4134C>T and c.5882G>A, p.Ala1038VAL and
p.His1406.Tyr, p.C1490Y@c4469G>A and p.L1850P:c.
5549T>C, p.R2106H:c.6317G>A, and p.F883L:c.2617T>C and
p.L1580S:c.439T>C.
Discussion
This study represents what we believe to be the ﬁrst
nationwide prospective study aimed at determining the
incidence and presenting characteristics of patients with
STGD. Herein, the incidence of STGD was found to be
0.127 per 100 000 population per year, which is much
lower than the rough estimate of 1 in 10 000 hitherto
repeatedly quoted in the literature. There is a possibility that
the incidence of STGD may be even higher than that re-
ported herein, because of incomplete ascertainment, which
is a known limitation of surveillance studies. Nonetheless, it
would be unlikely that the incidence would deviate mark-
edly from that estimated herein. It was not possible to know
whether reported cases for which baseline data were not
collected (n ¼ 11, 13.6%) (i.e., those cases reported but
from which questionnaires were not returned) were indeed
cases of STGD. Nonetheless, every effort was made to
retrieve all cases seen during the period of the study, not
only through active, prospective surveillance by the BOSU
but also through contacting the largest reference centers in
the UK for inherited retinal diseases. Furthermore, patients
initially reported who required additional testing to conﬁrm
the diagnosis of STGD were captured in the study by data
collected through the 6-month questionnaire.
STGD is often considered a form of juvenile macular
dystrophy.4,9,10 Based on current ﬁndings, it seems that
most patients present in early adulthood. As reported pre-
viously, however, the disease can have an onset at any
stage of life, with the oldest patient reported being in the
seventh decade of life.8 Furthermore, it is clear that,
although in most patients the disease is conﬁned to themacula, in a proportion, midperipheral/peripheral
anatomic and functional abnormalities are detected and,
thus, it would be more appropriate to classify STGD as
an “inherited retinal disease” instead of an “inherited
macular disease.”
The baseline characteristics identiﬁed in incident cases
of STGD in this study are overall in agreement with
previously published studies. Thus, approximately one-
third of patients presented with a vision of 0.30 log-
MAR (Snellen equivalent 20/40) or better, consistent with
published literature,8,11e13 and 18.6% (13/70) with a visual
acuity of 1.0 (20/200 Snellen equivalent) or worse in the
better-seeing eye. Retinal ﬂecks and macular atrophy are
the main clinical features of STGD.1 Herein, 50 patients
(71.4%) had retinal ﬂecks; in the vast majority macular
and/or midperipheral/peripheral retinal ﬂecks were
evident on slit-lamp biomicroscopy (n ¼ 43). However,
in some patients (n ¼ 7), ﬂecks were not apparent clini-
cally but were identiﬁed on AF imaging. This highlights
the importance of this imaging technology to aid the
diagnosis of STGD. It is well known, however, as Star-
gardt pointed out in his original description of the disease,
that ﬂecks are not always present at the outset but can
develop in time.1
The distribution of electrophysiology groups in the
current study is very similar to that previously reported,8
with group 1 (macular dysfunction alone) being the most
common and group 3 the least frequent (73% and 11% of
patients in the current study with group 1 and group 3
STGD, respectively, compared with 68% and 17% of
patients with group 1 and group 3 in our previous
study).8 The pattern of functional loss as determined by
FFERG and PERG has implications regarding disease
prognosis and hence it is essential for the counseling of
patients with STGD.8,14 Furthermore, the presence of a
ﬂat PERG is very characteristic of patients with STGD and
can be a very helpful feature, if present, to establish the
differential diagnosis between STGD and pattern dystro-
phy simulating STGD-FFM.8,15 In the latter, a normal or
nearly normal PERG can be identiﬁed.16 The other main
feature that allows this differentiation (and differentiating
between ABCA4 and Peripherin/RDS [PRPH2] disease) is
the presence of a relative peripapillary sparing in
STGD,17 not observed in patients with pattern dystrophy.
Interestingly, in a small proportion of patients (n ¼ 5)
with STGD presented herein, a normal PERG was
reported; 1 of these had conﬁrmed mutations in both
alleles of ABCA4. Thus, it appears that a normal PERG
can be present in a few patients with STGD and, thus,
this feature should not rule out the diagnosis of this
inherited retinal dystrophy. In patients with severe group
3 disease, the differentiation between STGD and retinitis
pigmentosa may be challenging; in both, diffuse retinal
abnormalities on slit-lamp biomicroscopy and widespread
functional loss (reduced rod and cone function) in elec-
trophysiology testing may be present. Under these cir-
cumstances, conventional AF (488 nm excitation) and
near-infrared AF (787 nm excitation), as well as the
PERG, may be useful disclosing a preserved central island
of AF (in conventional or near-infrared AF) and residual511
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reduced AF (in conventional AF and near-infrared AF) and
a ﬂat PERG in STGD.18,19
The current study suggests that fundus AF imaging and
PERG are widely used in the UK to aid in the diagnosis of
STGD. It also suggests that fundus AF imaging has super-
seded the more invasive FFA. During the period of the
study, genetic testing was rarely carried out. It is possible
that the scarce use of genetic testing related to the fact that,
unlike in other monogenic retinal dystrophies, results of
ABCA4 testing are not always easily interpretable. ABCA4
mutations are not exclusive of patients with STGD but can
be identiﬁed in other inherited retinal dystrophies, such as
bull’s-eye maculopathy,20 cone-rod dystrophy,21 and
retinitis pigmentosa.22 Furthermore, sequencing of the
complete coding sequence in patients with clinical features
of STGD often fails to reveal 1 or both ABCA4
mutations.5,23e25
Despite its possible limitations, this study provides a
more accurate estimate of the incidence of STGD and a
good indication of the presenting characteristics of these
patients. The insight gained is valuable to inform the design
of therapeutic trials for this condition.
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UK. E-mail: n.lois@qub.ac.uk.Pictures & PerspectivesAuramine-Rhodamine StaindDetection of Mycobacteria in Ocular Fluid
A 38-year-old male patient presented with a large subretinal mass in the left eye. There was massive exudation around the lesion and at the
periphery of the fundus (Fig 1A). The right eye was normal. A provisional diagnosis of choroidal granuloma due to tubercular etiology was
made. A biopsy sample of the vitreous humor was subjected to various investigations. An auramine-rhodamine stain of vitreous ﬂuid showed
acid-fast organisms exhibiting bright orange ﬂuorescence against a dark background, conﬁrming our diagnosis (Fig 1B). (Magniﬁed version
available at www.ophthalmologyretina.org).
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